Kawai K, Akaza H
Dept. of Urology, University of Tsukuba.
Gan To Kagaku Ryoho. 1996 Dec;23(14):1929-35.
Testicular cancer is recognized as a model of curable cancer by chemotherapy, and etoposide is the one of the most important drugs in its treatment. Etoposide has been used with cisplatin and bleomycin as a first-line combination chemotherapy since the early 1980s. It is now the key drug in the setting of high-dose chemotherapy for refractory cases. Oral, low-dose etoposide may provide effective palliation in some patients refractory to possible curative salvage therapy. Oral etoposide may also play a role in the maintenance therapy adjunctive to salvage therapy. Nevertheless, etoposide has failed to show definite therapeutic efficacy in the treatment of renal cell carcinoma and bladder cancer. The combination therapy of oral etoposide and estramustine, however, showed promising results for the treatment of hormone-refractory prostate cancer. Further investigations are required for this new treatment strategy for prostatic cancer.
睾丸癌被认为是一种可通过化疗治愈的癌症模型，而依托泊苷是其治疗中最重要的药物之一。自20世纪80年代初以来，依托泊苷一直与顺铂和博来霉素联合用作一线化疗药物。现在，它是难治性病例大剂量化疗中的关键药物。口服低剂量依托泊苷可能为一些对可能的根治性挽救治疗无效的患者提供有效的姑息治疗。口服依托泊苷在挽救治疗的辅助维持治疗中也可能发挥作用。然而，依托泊苷在治疗肾细胞癌和膀胱癌方面未能显示出明确的治疗效果。不过，口服依托泊苷与雌莫司汀的联合治疗在治疗激素难治性前列腺癌方面显示出了有希望的结果。这种前列腺癌的新治疗策略还需要进一步研究。
